# EDGAR Filing Document

**Accession Number:** 0001640266
**File Stem:** 0001104659-25-056835
**Filing Date:** 2025-6
**Character Count:** 9454
**Document Hash:** 42b99e22b63f9ec4fd24d6ed0d87f258
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-056835.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0001104659-25-056835

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250603

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Voyager Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001640266
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37625
- **FILM NUMBER:** 251027253

**BUSINESS ADDRESS:**
- **STREET 1:** 75 HAYDEN AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 857-259-5340

**MAIL ADDRESS:**
- **STREET 1:** 75 HAYDEN AVENUE
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **June 3, 2025**

**Voyager Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37625** | **46-3003182** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **75 Hayden Avenue**<br> **Lexington, Massachusetts** | **02421** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(857) 259-5340**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| Common Stock, $0.001 par value | VYGR | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

At the annual meeting of stockholders of Voyager Therapeutics, Inc. ("Voyager") held on June 3, 2025 (the "2025 Annual Meeting"), Voyager's stockholders approved the 2025 Stock Incentive Plan (the "2025 Stock Incentive Plan") and the Amended and Restated 2015 Employee Stock Purchase Plan (the "Amended and Restated 2015 Employee Stock Purchase Plan"), each of which had previously been adopted by Voyager's Board of Directors subject to stockholder approval.

Descriptions of the 2025 Stock Incentive Plan contained on pages 12 to 26 and the Amended and Restated 2015 Employee Stock Purchase Plan contained on pages 27 to 31 of Voyager's [Proxy Statement for the 2025 Annual Meeting, filed with the Securities and Exchange Commission on April 23, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm), are incorporated herein by reference. Complete copies of the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

The following is a summary of the matters voted on at the 2025 Annual Meeting.

&nbsp;&nbsp;&nbsp;&nbsp;**(a)** Voyager's stockholders elected Grace E. Colón, Ph.D., Catherine J. Mackey, Ph.D., Glenn Pierce, M.D., Ph.D., and George
Scangos, Ph.D., each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor has been
duly elected and qualified, subject to his or her earlier death, resignation, or removal. The results of the stockholders' vote
with respect to the election of such Class I directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Votes For** | **Votes<br> Withheld** | **Broker<br> Non-Votes** |
| Grace E. Colón, Ph.D. | 38209235 | 1688859 | 8531070 |
| Catherine J. Mackey, Ph.D. | 38216364 | 1681730 | 8531070 |
| Glenn Pierce, M.D., Ph.D. | 38123609 | 1774485 | 8531070 |
| George Scangos, Ph.D. | 33177695 | 6720399 | 8531070 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(b)** Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive
officers. The results of the stockholders' vote with respect to such proposal were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 37755432 |  | 2034622 |  | 108040 |  | 8531070 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(c)** Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting
firm for the fiscal year ending December 31, 2025. The results of the stockholders' vote with respect to such ratification were
as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** |
|  | 48137216 |  | 249172 |  | 42776 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(d)** Voyager's stockholders approved the 2025 Stock Incentive Plan. The results of the stockholders' vote with respect to such
proposal were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 28582188 |  | 11275604 |  | 40302 |  | 8531070 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(e)** Voyager's stockholders approved the Amended and Restated 2015 Employee Stock Purchase Plan. The results of the stockholders'
vote with respect to such proposal were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 36532540 |  | 3326824 |  | 38730 |  | 8531070 |

---

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [99.1](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm#AppendixA) | [Voyager Therapeutics, Inc. 2025 Stock Incentive Plan, incorporated herein by reference to Appendix A to Voyager's definitive proxy statement, filed with the Securities and Exchange Commission on April 23, 2025.](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm#AppendixA) |
| [99.2](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm#AppendixB) | [Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan, incorporated herein by reference to Appendix B to Voyager's definitive proxy statement, filed with the Securities and Exchange Commission on April 23, 2025.](https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000155837025005254/vygr-20250603xdef14a.htm#AppendixB) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 5, 2025 | **VOYAGER** **THERAPEUTICS, INC.** | **VOYAGER** **THERAPEUTICS, INC.** |
|  | By: | */s/ Alfred Sandrock, M.D., Ph.D.* |
|  |  | Alfred Sandrock, M.D., Ph.D. |
|  |  | Chief Executive Officer, President, and Director<br> *(Principal Executive Officer)* |

---